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Migraine is a common, recurrent, and disabling primary headache disorder with a genetic
component which affects up to 20% of the population. One third of all patients with
migraine experiences aura, a focal neurological disturbance that manifests itself as
visual, sensitive or motor symptoms preceding the headache. In the pathophysiology
of migraine with aura, activation of the trigeminovascular system from the meningeal
vessels mediates migraine pain via the brainstem and projections ascend to the thalamus
and cortex. Cortical spreading depression (CSD) was proposed to trigger migraine aura
and to activate perivascular trigeminal nerves in the cortex. Quinine, quinidine and the
derivative mefloquine are able to inhibit CSD suggesting an involvement of neuronal
connexin36 channels in CSD propagation. More recently, CSD was shown to induce
headache by activating the trigeminovascular system through the opening of stressed
neuronal Pannexin1 channels. A novel benzopyran compound, tonabersat, was selected
for clinical trial on the basis of its inhibitory activity on CSD and neurogenic inflammation
in animal models of migraine. Interestingly, in the time course of animal model trials,
tonabersat was shown to inhibit trigeminal ganglion (TGG) neuronal-glial cell gap junctions,
suggesting that this compound could prevent peripheral sensitization within the ganglion.
Three clinical trials aimed at investigating the effectiveness of tonabersat as a preventive
drug were negative, and conflicting results were obtained in other trials concerning
its ability to relieve attacks. In contrast, in another clinical trial, tonabersat showed a
preventive effect on attacks of migraine with aura but had no efficacy on non-aura attacks.
Gap junction channels seem to be involved in several ways in the pathophysiology of
migraine with aura and emerge as a new promising putative target in treatment of this
disorder.
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INTRODUCTION
Migraine is a common, recurrent, and disabling primary
headache disorder which affects up to 20% of the population
(Haut et al., 2006). The estimated annual prevalence of migraine
is 18.2% in women and 6.5% in men in the population of the
United States, and 16.8 and 7.5%, respectively, in European coun-
tries (Lipton et al., 2001; Stovner et al., 2006). Migraine preva-
lence varies with age and is highest in 35- to 45-year-old people.
Migraine is associated with significant reduction of health-related
quality of life and has an important socioeconomic impact.
Migraineurs report functional impairment with their headaches:
bed rest, absenteeism from work or school, reduced effective-
ness, disruption of household work, family or social activity.
On the basis of clinical and descriptive criteria, and headache
features, the second edition of the Classification of Headache
Disorders divided migraine into five major categories, the two
most important of these are migraine without aura and migraine
with aura. About one third of all patients with migraine experi-
ences aura, a focal neurological disturbance that manifests itself
as visual, sensitive or motor symptoms preceding the headache.
The classification also acknowledges rare forms of this disease
as familial hemiplegic migraine, the first migraine syndrome to
be linked to a specific set of genetic polymorphisms (Lipton
et al., 2004). Whereas there are evidences for a genetic contri-
bution to migraine and that environmental factors also play a
role, the brain events that initiate migraine remains unclear. This
disease is underdiagnosed and also undertreated. Traditionally,
treatment for migraine is divided into acute and preventive
approaches, aimed at stopping the evolving attack or stopping the
onset of attacks, respectively. Drugs used in acute treatment tar-
get the serotonergic system (triptans and ergot derivatives), the
inflammatory reaction [non-steroidal anti-inflammatory drugs
(NSAIDs), aspirin] or calcitonin gene-related peptide (CGRP)
receptors (gepants). Some preventive drugs target the central
nervous system (CNS) inhibitory [gamma-aminobutyric acid
(GABA) receptors] and excitatory systems (glutamatergic neu-
rotransmission, ion channels) and belong to the family of
antiepileptic drugs. α1 blockers (oxetorone, indoramine) and β1
blockers (propranolol, metoprolol) can also be used in migraine
prophylaxis.
www.frontiersin.org February 2014 | Volume 5 | Article 78 | 1
Sarrouilhe et al. Gap junctional communication in migraine
Recent studies show that gap junction channels seem to be
involved in several ways in the pathophysiology of migraine with
aura (Sarrouilhe and Dejean, 2012; Karatas et al., 2013). A novel
benzopyran compound, (-)-cis-6-acetyl-4S-(3-chloro-4-fluoro-
benzoylamino)-3,4-dihydro-2,2-dimethyl-2H-benzo[b]pyrane-3
S-ol (SB-220453, tonabersat), was selected for clinical trials as an
anti-migraine agent. Preclinical studies showed that tonabersat
inhibited cortical spreading depression (CSD) and neurogenic
inflammation in animal models of migraine (Durham and
Garrett, 2009). CSD is a wave of electrical activity that moves
across the cerebral cortex and was proposed to trigger migraine
aura and to induce migraine headache (Charles and Baca, 2013).
In the time course of animal model trials, tonabersat was shown
to inhibit neuronal-glial gap junctions in trigeminal ganglion
(TGG), suggesting that this compound could prevent peripheral
sensitization within the ganglion (Damodaram et al., 2008).
Moreover, the signaling cascade that takes place between CSD
induction and activation of the trigeminovascular system was
recently elucidated and involved a transient opening of stressed
neuronal pannexin1 (Panx1) channels (Karatas et al., 2013). The
results of the clinical trials and pharmacokinetic studies indicate
that tonabersat is more suitable as a daily prophylactic drug
for migraine with aura attacks than in the acute treatment of
migraine (Hauge et al., 2009; Silberstein, 2009).
The purpose of this review is to provide up-to-date informa-
tion of our knowledge about the involvement of gap junction
channels in migraine with aura pathophysiology and their emerg-
ing role as potential targets in prophylaxis treatment of this
disease.
GAP JUNCTION CHANNELS AND HEMICHANNELS IN THE
CENTRAL NERVOUS SYSTEM
Gap junctions are specialized regions of the plasma mem-
branes of adjacent cells, separated by an intercellular space
(gap) of 2–3 nm, where transmembrane channels are clustered in
microdomains. Gap junction channels assemble from the docking
of two hemichannels, each of them originating from cells in con-
tact. These channels connect the cytoplasms of the adjacent cells
and allow the intercellular passage (gap-junctional intercellular
communication; GJIC) of small molecules up to approximately
1 kDa (cAMP, IP3, metabolites, sugars, siRNA, and small pep-
tides). Each hemichannel (or connexon) is an oligomerized hex-
amer of proteins called connexins (Cxs), surrounding an aqueous
pore (1–1.5 nm diameter). To date, 20 members of the Cx fam-
ily have been identified in mice and 21 in humans (Rackauskas
et al., 2010). Cxs are expressed in all tissues except differenti-
ated skeletal muscles, erythrocytes, mature sperm cells and are
restricted to certain adult neuronal subpopulations (Söhl et al.,
2004). Most cell types express multiple Cx isoforms, and therefore
homotypic, heterotypic, and heteromeric gap junction channels
may form between cells (Kumar and Gilula, 1996). Cxs have
four hydrophobic membrane-spanning domains, two conserved
extracellular domains (E1, E2) and three cytoplasmic domains
such as both extremities and a loop between transmembrane
domains 2 and 3. The C-terminal tail region, diverse in size and
sequence, can be phosphorylated (except Cx26) and mediates
interactions with partner proteins (Hervé et al., 2004; Sosinsky
and Nicholson, 2005). A new protein family called Panxs (Panx1,
2, and 3) was recently discovered and classified as gap junction
proteins due to their homology (25–33% identity) to the more
than 25 innexins (Inxs) that have been identified as gap junction
proteins of Invertebrates (Yen and Saier, 2007). However, Panxs
bear no sequence homology with Chordate Cxs and current stud-
ies indicate that Panxs cannot form gap junction channels in vivo.
In contrast, Panxs can form hemichannels that allow diffusion of
ions and small molecules between intra and extracellular com-
partments. In Vertebrates, the largely overlapping distribution of
Panxs and Cxs in tissues renders themolecular identity of the pro-
tein forming hemichannels at non-junctional membrane difficult
to establish (Scemes, 2012). Gap junction channels play critical
roles in many signaling processes, including coordinated cardiac
and smooth muscle contraction, neuronal excitability, neuro-
transmitter release, insulin secretion, and others. The degree of
GJIC is sensitive to a variety of stimuli, including growth fac-
tors, hormones, cytokines, neurotransmitters, lipophilic agents
(alcohols, fatty acids, steroids, and others), changes in the level
of intracellular Ca2+, pH, in transjunctional applied voltage and
in phosphorylation/dephosphorylation processes (Budunova and
Williams, 1994; Hervé and Sarrouilhe, 2005).
Cxs are largely represented in the CNS with eleven Cx sub-
types (Cxs26, 29, 30, 32, 36, 37, 40, 43, 45, 46, 47). Some of them
are expressed in the same cell type, forming intercellular chan-
nels with different structural combinations and properties whose
physiological significance remains largely unknown (Nakase and
Naus, 2004). GJIC is observed between astrocytes, oligodendro-
cytes, neurons (electrical synapses), microglia, ependymal cells as
well as between neurons and astrocytes, and astrocytes and oligo-
dendrocytes (Nakase and Naus, 2004; Orthmann-Murphy et al.,
2007). In the nervous system, Cx43, Panx1, and Panx2 can form
hemichannels at non-junctional membrane which physiological
and pathophysiological roles remain to be determined (Kar et al.,
2012). In the last decade, the link between inherited mutations
in Cx genes, gap junction channel loss of function and human
central (Cx47 and type 1 Pelizaeus-Merzbacher-like disease; Cx43
and oculodentodigital dysplasia) and peripheral (Cx32 and type
1 Charcot-Marie-Tooth disease) neuropathies was firmly estab-
lished (Zoidl and Dermietzel, 2010; Abrams and Scherer, 2012).
Changes in Cx expression and GJIC capacity were described in
brain injuries and dysfunctions as inflammation, epilepsy, and
neurodegenerative diseases (Rouach et al., 2002). Thereby, gap
junction channels have progressively appeared as potential ther-
apeutic targets in the treatment of a growing number of CNS
diseases (Alldredge, 2008).
MIGRAINE WITH AURA
PATHOPHYSIOLOGY OF MIGRAINE WITH AURA
Progresses in understanding the pathophysiology of migraine was
made in recent years (Goadsby et al., 2009a; Olesen et al., 2009).
Even if the brain events in the development of migraine with aura
are unclear in human, experimental data in murine corroborated
by clinical observations allowed to propose a chronology of events
linking aura and headache (Bolay et al., 2002). Neuroimaging
and experimental studies suggested that CSD triggered migraine
aura and was responsible of activation of the trigeminovascular
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system and possibly migraine headache (Figure 1). CSD is a
transient disturbance in electroencephalographic activity charac-
terized by slow wave of neuronal and glial depolarization, that
self-propagates at a speed of 2–5mm/s across the brain cortex or
other brain areas (Charles and Baca, 2013). The depolarization
phase of CSD is associated with a transient increase in cere-
bral blood flow. This depolarization is followed by a long-lasting
suppression of neuronal activity accompanied by a prolonged
decrease in cerebral blood flow. GJIC, and non-junctional Cx-
containing hemichannels, have been proposed to be involved in
CSD, and gap junction blockade would represent a possible ther-
apeutic strategy (For review, see Costa et al., 2013). CSD causes
large shifts in cortical extracellular ionic composition (H+, K+),
pH, metabolites (nitric oxide (NO), arachidonic acid), and neu-
rotransmitter (glutamate) concentrations (Bolay et al., 2002).
These molecules diffuse locally, depolarize or sensitize perivas-
cular nociceptive trigeminal afferents in pia mater (peripheral
sensitization), which, in turn, sensitize and increase neural activ-
ity in the ipsilateral TGG and in the caudal portion of the
trigeminal nucleus (TGN) in the brainstem (central sensitiza-
tion). In the same time, collateral axons of activated neurons in
the TGG release proinflammatory peptides (neurokinin A, CGRP,
substance P) in the dura mater, leading to a local sterile inflam-
matory reaction (i.e., in the absence of infection) and then to
headache. Moreover, a central trigeminal-parasympathetic reflex
produces vasodilatation of dura mater (and pia mater) vessels.
For this, the activation of the TGN, in turn, also induces a
stimulation of the superior salivary nucleus (SSN) of the brain-
stem and perivascular parasympathetic efferents of the duramater
via the sphenopalatine ganglia (SPG). Postganglionic parasympa-
thetic efferents release vasoactive molecules (vasoactive intestinal
polypeptide, NO, acetylcholine) into the dura mater, promote
vasodilatation and hyperemia and then could also explain auto-
nomic symptoms that frequently occur during migraine attack.
The perception of pain is mediated by rostral projections from
the TGN to brain structures. It was proposed that in the attack
of migraine with aura, nociception almost originated from pial
perivascular trigeminal afferents with a later contribution from
dural perivascular ones (Olesen et al., 2009).
The cellular mechanisms of initiation and propagation of CSD
is still poorly understood. Astrocytes are highly interconnected
by gap junctions and conduct signals in the form of intercellular
Ca2+ waves. Transmission of Ca2+ waves may involve cell-to-
cell diffusion of Ca2+-mobilizing second messengers through
the gap junction channels between astrocytes, and the extra-
cellular release of ATP through Cx43 and Panx1 hemichannels.
ATP, in turn, can potentially act on the adjacent and /or dis-
tant astrocytic population, in an autocrine/paracrine fashion,
thus amplifying the extent to which Ca2+ waves are trans-
mitted (Scemes and Giaume, 2006). It was proposed that gap
junction-mediated propagation of Ca2+ waves in astrocytes may
represent the advancing front of CSD but that other factors,
FIGURE 1 | Pathophysiology of migraine with aura. A slow wave of
neuronal and glial depolarization, cortical spreading depression (CSD), has
been implicated in the mechanism of migraine aura. Moreover, CSD induces
an opening of stressed neuronal Panx1 channels with subsequent release of
proinflammatory mediators. These mediators activated astrocytes of the glia
limitans leading to a continuous release of cytokines, prostanoids and nitric
oxide to subarachnoid space (1). These molecules diffuse locally and
depolarize and sensitize perivascular trigeminal terminals in pia mater (2,
peripheral sensitization). In turn, the caudal portion of the trigeminal nucleus
(TGN) of the brainstem is activated and sensitized (3, central sensitization).
Collateral axons of activated neurons in the trigeminal ganglion (TGG) release
proinflammatory peptides in the dura mater, inducing a sterile inflammatory
reaction and then a headache (4). Moreover, a central
trigeminal-parasympathetic reflex, originating from TGN and mediated
through the superior salivary nucleus (SSN) of the brainstem and the
sphenopalatine ganglia (SPG), produces vasodilatation of dura mater vessels
(5–7). Pain perception is mediated by projections from the TGN to brain
structures (8). Redrawn and modified after (Sarrouilhe and Dejean, 2012).
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including K+ and glutamate, are necessary for sustained propa-
gation (Martins-Ferreira et al., 2000). The N-methyl-D-aspartate
(NMDA) receptor antagonist, MK-801, blocks CSD but, unlike
the gap junction blocker carbenoxolone, does not inhibit trans-
mission of Ca2+ waves (Peters et al., 2003). So, the advancing
front of CSDmay contribute to the trigger of the depolarization of
surrounding neurons, leading to further release of glutamate and
K+ into the extracellular environment. Interestingly, astrocytic Cx
hemichannels can contribute to the release of glutamate in the
extracellular space (Ye et al., 2003). Glutamate, in turn, through
the NMDA receptor may then stimulate cytosolic Ca2+ oscilla-
tions in astrocytes, allowing CSD propagation (Martins-Ferreira
et al., 2000). More recently, the signaling cascade that takes place
between CSD induction and activation of the trigeminovascular
system was elucidated in mice (Karatas et al., 2013). It is now
evident that Panx1 is functionally linked to the purinergic P2X7
receptor and that the two proteins may also interact physically.
Moreover, one or both of these proteins may be directly linked
with the inflammasome, a multiprotein complex that mediates
the innate inflammatory response (MacVicar and Thompson,
2009; Dahl and Keane, 2012). CSD induces a transient opening
of stressed neuronal Panx1 channels with subsequent activa-
tion of the inflammasome, leading to a cleavage of caspase 1 to
its proteolytic form and a release of pro-inflammatory agents
[high-mobility group box 1 (HMGB1), interleukin-1β (IL-1β)],
both of which take part in the initiation of the inflammatory
response (Silverman et al., 2009; Karatas et al., 2013). Nuclear fac-
tor KappaB (NF-κB) is activated and translocated to the nucleus
followed by cyclooxygenase-2 (COX2) and inducible nitric oxide
synthase (iNOS) induction in astrocytes forming the glia limitans.
The parenchymal inflammatory response leads to a continuous
release of cytokines, prostanoids and NO to subarachnoid space
that, in turn, promotes a prolonged activation of the perivascu-
lar nociceptive trigeminal afferents in pia mater. So, in contrast
to mediators such as H+ and K+ that are transiently released
during CSD, the parenchymal inflammatory response may pro-
vide continuous release of mediators required for sensitization of
trigeminal nerve endings and lasting headache. The inhibition of
Panx1 channel by carbenoxolone abolishes caspase 1 activation,
NF-κB translocation and trigeminal activation. These results sug-
gest that Panx1 channels may play a role as a reporter linking
neuronal stress to inflammatory reaction (Karatas et al., 2013).
The genetic influences of migraine at the population level are
largely unknown. Progress in genetic analysis has been largely
restricted to rare monogenic subtypes of migraine as famil-
ial hemiplegic migraine. Recent genome-wide association study
(GWAS) allowed the identification of various susceptibility loci
for common forms of migraine. The minor allele of rs1835740
on chromosome 8q22.1 was identified to be associated with
migraine, and particularly in individuals withmigraine with aura.
Rs1835740 is located between two genes involved in glutamate
homeostasis, suggesting a possible link between the identified
variant and the regulation of a neurotransmitter that has long
been suspected to play a role inmigraine pathophysiology (Antilla
et al., 2010). The TRESK K2P potassium channel, encoded by
the KCNK18 gene (10q25.3) and known to be involved in pain
pathways, has been linked to migraine with aura in a single
family (Lafrenière et al., 2010). In another GWAS, three sus-
ceptibility loci for common forms of migraine (with or without
aura) were identified and suggested a shared pathophysiology
among migraine with or without aura. TRPM8 (2q37.1) encodes
a member of the transient receptor potential (TRP) superfamily
of channels that is involved in neuropathic pain; LRP1 (12q13.3)
encodes a receptor that could modulate glutamatergic synap-
tic transmission; PRDM16 (1q36.32) which potential role in
migraine is unclear (Chasman et al., 2011).
Then, in genetically susceptible patients, mutations in these
genes may reduce the threshold for CSD. Triggers of migraine
attacks would induce CSD in such a hyper-excitable cortex by
modifying the activity of ionic channels and then by altering
ionic flow across cell membrane (Chakravarty, 2010). However,
the respective roles and interaction of genetic and environmental
factors in this multifactorial disorder remain to be determined.
ANTI-MIGRAINE THERAPY
Treatment for migraine is divided into acute and preventive
approaches, aimed at stopping the evolving attack (relief of symp-
toms) or reducing the frequency of occurrence of attacks, respec-
tively (Figure 2). The chronic treatment may last more than 1
year depending on the evolution of the disease. Acute treatment
of vasodilatation and pain during attacks can control symptoms
in 70% of attacks.
“Acute” therapy
Painful symptoms, arising from vasodilatation of cerebral vessels
and inflammatory processes, require medication with powerful
and fast action. The effectiveness of an acute therapy of migraine
mainly depends on its earliness.
Some serotonergic agonists, which are antimigraine drugs with
vasoconstrictive action, have high efficacy and are widespread
prescribed. Ergot derivatives, which exert vasoconstrictive effect
through the activation of 5HT1A,1B,1D receptors, are also
dopaminergic and adrenergic antagonists. Only two molecules
are indicated in migraine attacks: ergotamine (exclusive use) and
dihydroergotamine also used for prophylaxis. For all these drugs,
there are oral, nasal and injectable forms, suitable for emergency
treatment. Triptans cause vasoconstriction of the meningeal ves-
sels by their agonist effect on the serotonin receptor 5-HT1B.
They also induce an inhibition of pro-inflammatory neuropep-
tide release by trigeminal nerve endings through the activation
of 5-HT1D receptors. However, the effectiveness of triptan treat-
ment during the aura phase remains controversial (D’Andrea
et al., 2011). Indeed, it was proposed that the blood-brain bar-
rier remains impermeable to triptans during the aura. Moreover,
according to a study made with sumatriptan, the incorporation
of 5-HT1D receptors in the synaptic membrane would occur only
after the onset of headache (Aurora et al., 2009). Because of their
vasoconstrictive properties, triptans cannot be used in patients
with vascular risk factors.
Migraine headache is associated with trigeminal nerve activa-
tion and CGRP release from the trigeminovascular system. CGRP
is a vasodilatory neuropeptide and development of its antagonists
is supported by the fact that they were highly effective in the treat-
ment of migraine attacks (Edvinsson et al., 2012). Olcegepant,
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FIGURE 2 | Some targets of anti-migraine drugs. Drugs written in red have been shown to exert an inhibitory effect on CSD.
telcagepant, MK-3207 and BI 44370 TA constitute the new family
of the gepants. They have displayed efficacy without vasocon-
strictive effect, with fewer adverse effects and longer period than
triptans (Costa et al., 2013). Moreover, the gepants have been
reported to inhibit CSD (Figure 2).
The inflammatory reaction associated with themigraine is also
a therapeutic target for some medications. Aspirin and NSAIDs
such as ketoprofen, ibuprofen, diclofenac are effective on attacks
of mild to moderate intensity. They act by inhibiting cyclooxyge-
nase, and thus, prevent the synthesis of pro-inflammatory media-
tors, such as prostaglandins. Acetaminophen, despite widespread
use, was poorly investigated as an anti-migraine drug. Anti-
migraine agents can be addressed in combination to improve
treatment compliance, efficacy or tolerability. For example, a
triptan can be used 2 h after failure to NSAID treatment.
The use of antiemetics (metoclopramide or domperidone) in
acute migraine attacks is recommended because these drugs
can improve the absorption of co-administered analgesics (Evers
et al., 2009).
Migraine prophylaxis
Migraine prophylaxis is recommended when seizure frequency
increases (more than two attacks per month) and/or intensity
of the symptoms, as well as the duration of the aura. To reduce
these parameters (frequency, intensity, or duration of crisis), a
variety of drugs (sometimes off-label) acting through various
mechanisms can be used.
Some of migraine drugs act through the serotonin recep-
tors (pizotifen, methysergide, dihydroergotamine, oxetorone),
calcium and sodium voltage-gated channels (flunarizine or anti-
epileptics such as gabapentin, valproate, topiramate, and lam-
otrigine) or the glutamatergic neurotransmission (lamotrigine).
Besides, topiramate and valproate are also GABA receptor ago-
nists. Lamotrigine is an anti-epileptic drug that would specifically
prevent migraine with aura (Lampl et al., 2005). A tricyclic
antidepressant, amitriptyline, may prevent the secretion of neu-
rotransmitters by modulating calcium channels (Wu et al., 2012).
Moreover, the glutamatergic antagonism, as a protective action
of neural response to CSD, is currently investigated (Olesen and
Ashina, 2011). Adrenergic blockers can also be used to act on the
vascular system (α-blockers: oxetorone, indoramine and antihy-
pertensive β1 blockers: propranolol, metoprolol). Vascular reac-
tivity is also modulated by inhibitors of angiotensin converting
enzyme (lisinopril) and inhibitors of angiotensin II (telmisartan,
candesartan). Naproxen, a NSAID, is used in prophylaxis as a
modulator of inflammation. This is also the case of aspirin for
treating migraines with aura. Finally, the mechanism of action of
botulinum toxin (which inhibits the release of acetylcholine) has
not been solved and the effectiveness of this toxin in prophylactic
treatment appeared to be controversial in recentmulticenter stud-
ies (Bekkelund and Alstadhaug, 2011; Marmura and Silberstein,
2011).
Drugs used in migraine prophylaxis (amitriptyline,
methysergide, gabapentin, lamotrigine, topiramate, valproate,
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and propranolol) have been shown to experimentally suppress
CSD susceptibility (Figure 2). Acute administration of these
drugs was ineffective, only longer treatment duration produced
CSD suppression (Costa et al., 2013). CSD-associated blood flow
changes are experimentally modulated by α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA) and GABA receptors,
suggesting that these receptors constitute targets of migraine
therapy in inhibiting CSD (Holland et al., 2010). Furthermore,
NR2B-containing NMDA receptors were shown to be key media-
tors of CSD, and as such, memantine- and some NR2B-selective
antagonists may be useful therapeutic agents for the treatment of
migraine with aura (Peeters et al., 2007).
In conclusion, if synapses, ionic channels, neurotransmitter
receptors of neurons are numerous targets for such prophylactic
treatment, the role of gap junction channels in CSD propaga-
tion, activation of the trigeminovascular system and peripheral
(and central, see below) sensitization opens new perspectives of
research.
GAP JUNCTION CHANNELS AS THERAPEUTIC TARGETS
PRECLINICAL STUDIES
Structure-activity relationship study of a new class of potential
antimigraine agents identified tonabersat, a novel cis benzopyran,
on the basis of its high efficacy at inhibiting neuronal hyper-
excitability and trigeminal nerve stimulated neurogenic inflam-
mation in rodent models (Chan et al., 1999). A release of NO
occurs during the headache phase of a migraine attack and
it is proposed that NO plays a pivotal role in depolarization
and sensitization of perivascular nociceptive trigeminal affer-
ents. Intraperitoneal administration of tonabersat (10mg·kg−1)
potently inhibited NO release following a cortical KCl stimulus
in anaesthetized cats (Read et al., 2000). In a further work using
the same anaesthetized cat model, tonabersat produces a marked
dose-dependent inhibition of repetitive CSD and reduces CSD-
induced repetitive episodes of pial artery vasodilatation (Smith
et al., 2000). When compared with the serotoninergic agonist
sumatriptan (5-HT1D,1B agonist), tonabersat seemed to be devoid
of adverse cardiovascular side-effects in isolated human tissues
(MaassenVanDenBrink et al., 2000). In a study using repetitive
diffusion-weightedMR imaging, the inhibitory effects of tonaber-
sat on CSD event number and duration of activity was confirmed
in vivo in the cat cerebral cortex. The drug also reduced sig-
nificantly the magnitude of the cortical area involved in CSD
episodes (Bradley et al., 2001). There is increasing evidence for
a role of a dura mater neurovascular event, involving reflex acti-
vation of the parasympathetic nervous system, in migraine with
aura attack. The effects of tonabersat were investigated in a model
of trigeminal nerve parasympathetic neurovascular reflexes in
anaesthetized cats, in which stimulation of the TGG produces an
increase in carotid blood flow. Intravenous infusion of tonaber-
sat (3.4μmol·h−1) produced 4 h later a maximal inhibition of
the neurovascular reflex (30% compared to control) whereas an
intraduodenal administration (10mg·kg−1) produced it (55%
inhibition) 2 h later (Parsons et al., 2001). In spite of its broader
spectrum of activity, tonabersat has been well tolerated and is
devoided of CNS adverse effects, even at high doses. While clinical
trials were started, a new mechanism of action was proposed for
this drug (Damodaram et al., 2008). Within the TGG, cell bodies
of afferent neurons are completely surrounded by several satellite
glial cells that can influence neuronal activity by controlling their
chemical environment. In rat, dye-coupling experiments demon-
strated that neuronal-satellite cells can communicate via gap
junction channels following neuronal activation in response to
inflammatory stimuli rather than under normal basal conditions.
These results suggested that neuronal-satellite glial cell signaling
is involved in initiating and maintaining peripheral sensitization
in the TGG and, thus, initiates migraine (Thalakoti et al., 2007).
Under basal conditions, qPCR analysis of total RNA extracted
from rat TGG allowed to detect mRNA of various Cxs (Cx26,
Cx36, Cx40, and Cx43). Immunochemical analysis showed that
Cx26 plaque formation between neurons and satellite cells was
transiently increased in response to acute temporomandibular
joint inflammation, and was sustained in chronic joint inflamma-
tion. Cx36 and Cx40 expression was shown to be only increased
in neurons where they may form hemichannels. In contrast,
Cx43 expression was not increased in TGG cells during acute or
chronic joint inflammation. The temporomandibular joint model
showed that inflammation duration was accompanied by differ-
ential Cx expression changes in TGG cells allowing increased
GJIC between neurons and satellite cells (Garrett and Durham,
2008). Intraperitoneal administration of tonabersat (10mg·kg−1)
inhibited neuronal-satellite cell GJIC in TGG likely through a
decrease of Cx26 expression since tonabersat treatment reduced
Cx26 staining and number of junctional plaques (Damodaram
et al., 2008). First, the results suggested that the high affinity and
stereospecific binding site for tonabersat could be neuronal-glial
cell gap junctions (Chan et al., 1999). Second, tonabersat should
be able to prevent peripheral sensitization within the TGG.
Carbenoxolone, a potent blocker of both Cx43-made gap junc-
tions and hemichannels and purinergic P2X7 receptor-associated
Panx1 hemichannels completely suppressed central sensitization
in an in vivo acute dental inflammation rat model and signif-
icantly attenuated it in an in vivo rat neuropathic pain model
(Chiang et al., 2010; Wang et al., 2014). These results suggest that
gap junctions and/or hemichannels play a critical role in mediat-
ing central sensitization in nociceptive neurons of the brainstem
trigeminal subnucleus caudalis (often termed themedullary dorsal
horn).
Probenecid, a well-established drug for the treatment of gout,
is a powerful inhibitor of Panx1 hemichannels. Interestingly,
Cx46 channels and the chimera Cx32E143 channels (where the
sequence of the first extracellular loop of Cx32 is replaced by
that of Cx43) are not affected by probenecid (Silverman et al.,
2008). In an in vivo rat model of migraine involving the sys-
temic administration of the NO donor nitroglycerin, probenecid
pre-treatment was shown to block the inflammatory process in
the caudal TGN, also involved in the pathogenesis of migraine.
Probenecid being also a non-selective inhibitor of multidrug
resistance-associated protein and organic anion transporters, fur-
ther studies are needed to determine the exact mechanism of the
modulatory effect of this drug in trigeminal activation (Vamos
et al., 2009).
Another study has shown that quinine, quinidine, and meflo-
quine are able to inhibit CSD in a rat neocortical slice model
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in vitro (Margineanu and Klitgaard, 2006). The alkaloids qui-
nine, quinidine and the derivative mefloquine, commonly used
as antimalarial drugs are known to reversibly and specifically
abolish current through Cx36 channels (and with lesser potency
through Cx50 channels) in transfected mammalian cells (Hervé
and Sarrouilhe, 2005). The binding site for quinine is proposed to
be intracellular, possibly within the pore of the gap junction chan-
nel (Srinivas et al., 2001). These results suggest an involvement
of neuronal Cx36 channels in CSD propagation and might bear
potential relevance for migraine with aura therapy (Margineanu
and Klitgaard, 2006).
In conclusion, the preclinical studies identified tonabersat as a
candidate for clinical evaluation of the treatment of migraine and
gap junction channels as a potential therapeutic target.
CLINICAL TRIALS
A randomized, double-blind crossover, placebo-controlled study
investigated the efficacy of tonabersat in the human experi-
mental migraine model in which glyceryltrinitrate was used to
induce migraine (Tvedskov et al., 2004). This two-center study
(Denmark, UK) included 15 patients (18–55 years old), with 6–36
migraines without aura attacks per year. Patients were scheduled
to have 2 study days separated by at least 11 days. On both study
days, oral administration of tonabersat (40mg) or placebo was
followed 60min after by glyceryltrinitrate infusion (0.5μg/kg per
min for 20min in the cubital vein). The study was stopped prema-
turely after the unexpected observation of episodes of hypoten-
sion in 4 patients, which in two cases led to serious adverse
events, suggesting a possible interaction between tonabersat and
glyceryltrinitrate when the two compounds were concurrently
administered. In the nine patients where comparison could be
made, no significant preventive anti-migraine activity could be
detected when tonabersat was compared with placebo. However,
the number of treated patients in this study was too small to show
any significance.
A second randomized, double-blind parallel group, placebo-
controlled, multicenter (Denmark, Hungary, South Africa), phase
II study further investigated tonabersat as a putative migraine
prophylactic agent (Goadsby et al., 2009b). The clinical trial
recruited patients (18–55 years old) experiencing between 2 and 6
migraine attacks (with or without aura) per month, for ≥ 1 year.
The International Headache Society criteria for migraine with
aura and migraine without aura were used to establish the diag-
nosis (Headache classification subcommittee of the International
Headache Society, 2004). In total 160 patients were enrolled for
a 4-week baseline observation period, after which 124 were ran-
domized. The patients orally received tonabersat 20mg daily (or
matching placebo) for 2 weeks and 40mg daily (or placebo) for
further 10 weeks. 123 patients provided usable efficacy data, 58 in
the tonabersat arm and 65 in the placebo arm. The study failed
on its primary endpoint, the change in mean monthly migraine
days from baseline to month 3 of the treatment period. In con-
trast, tonabersat had promising statistically significant effects on
two predetermined secondary endpoints among ten, the change
in the mean monthly consumption of rescue medication from
the baseline period to month 3, and the overall 50% responder
rate at 3 months. Unexpectedly, placebo responses were high for
all endpoints and may have compromised the outcome of the
study. However, the secondary endpoints data and the fact that
tonabersat was very well tolerated support further exploration of
this compound in a larger scale clinical trial.
A further single-center, randomized, double-blind parallel
group, placebo-controlled phase IIb tonabersat evaluation in
migraine prevention in the US (TEMPUS) involved approxi-
mately 500 patients with episodic migraine with or without aura.
The TEMPUS study was significantly longer than the 3 months
treatment period in the earlier phase IIa trial since the earlier trial
showed that tonabersat was more effective toward the end of the
3 months period. The fact that tonabersat was very well tolerated
in the previous study, allowed to explore the effects of increas-
ing the dose (Goadsby et al., 2009b). Following a 4-week baseline
observation period, the patients received either tonabersat (40 or
80mg) or placebo on a once-daily basis. The 20-week study did
not meet its primary endpoint of reducing the migraine attacks
suffered by patients during the last 8 weeks of the 20-week treat-
ment period compared to baseline period. A detailed analysis of
the TEMPUS results has not been published (Peroutka, 2009).
An important step was taken forward with a fourth, single-
center (Denmark), randomized, double-blind crossover, placebo-
controlled phase II clinical trial. In contrast to the former, this
study only included patients having migraine with aura exhibit-
ing frequent aura attacks (Hauge et al., 2009). The study involved
39 patients (18–65 years old) who had at least 1 aura attack per
month during the past 3 months. As previously reported, the
patients suffering migraine with aura who were involved in the
study had attacks with and without aura (Eriksen et al., 2004).
Eight patients were excluded during the study and 31 completed
the trial and were analyzed. Two treatment periods of 12 weeks
(tonabersat and then placebo or placebo and then tonabersat)
were separated by a washout period of 4 weeks with placebo.
During each 12-week treatment period, tonabersat or matching
placebo dose was increased from 20 to 40mg at week 3. For the
first primary endpoint, a significant reduction in the number
of aura attacks, with or without headache, was observed during
treatment with tonabersat compared with placebo. The median
number of attacks of aura followed by headache was also signifi-
cantly reduced. In contrast, the trial failed on its second primary
endpoint, the reduction in migraine headache days with or with-
out aura. The results showed that the gap junction antagonist,
tonabersat, also known to inhibit CSD, has a preventive effect
in migraine with aura but no efficacy on days with any type
of migraine. These results are in agreement with previous stud-
ies using functional neuroimaging that have shown that cerebral
spreading hypoperfusion, and probably CSD, are present only in
migraine with aura (Sanchez del Rio and Alvarez Linera, 2004;
Costa et al., 2013). Up to now, there is no direct evidence that CSD
is the initiating mechanism in migraine without aura. The results
of this crossover clinical trial do not support previous observa-
tion suggesting that an asymptomatic CSD is involved in attacks
of migraine without aura (Woods et al., 1994). This small clini-
cal trial requires confirmation in a larger randomized controlled
preventive study in patients with migraine with aura.
However, what is the efficacy of tonabersat in the acute treat-
ment of migraine? In 2009, two original articles described, in the
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same issue of Cephalalgia, the results of three multi-center phase
II clinical trials that explored the ability of tonabersat to relieve the
symptoms of migraine attacks. These randomized, double-blind
parallel-group, placebo-controlled, multi-center, studies included
patients (between 18 and 65 years old) sufferingmigraines with or
without aura for at least 1 year before the trial, with 1–6 attacks
each month. In the first study evaluating tonabersat as an acute
treatment of migraine, the clinical trial was conducted in 53 cen-
ters in 12 countries (Dahlöf et al., 2009). A total of 693 patients
suffering from migraine with or without aura were screened,
among which 667 were enrolled and randomized to treatment
in a 1:1:1:1 ratio. Patients received 20 or 40mg of tonabersat, or
50mg sumatriptan as a positive control, or placebo in a single oral
dose at the onset of a moderate or severe attack. Among the 667
patients enrolled and randomized, 541 received allocated inter-
vention and the results were analyzed for 406 of them. Tonabersat
(20 or 40mg) did not provide a significant advantage over placebo
in headache relief determined 2 h after treatment (primary end-
point). Headache relief (rated on the International Headache
Society scale), which is self-evaluated by the patient, is defined as a
change in severity of the migraine symptoms from grade 2 (mod-
erate) or 3 (severe) at pretreatment to grade 0 (none) or 1 (mild)
2 h after the treatment. Tonabersat had no effect on any sec-
ondary outcome variable, complete abolition of headache at 2 h
and headache relief at 1 and 4 h, compared with placebo (Dahlöf
et al., 2009). The efficacy of tonabersat in the acute treatment of
migraine attacks has also been assessed in two other large clinical
trials, one conducted in Europe, Australia, South Africa (named
international study), and one in North America (USA, Canada)
(Silberstein et al., 2009). In the International study, 549 patients
were screened, among which 525 were enrolled and randomized
and 441 received allocated intervention. In the North American
study, 534 patients were screened, among which 506 were enrolled
and randomized and 418 received allocated intervention. Patients
took a single oral dose of tonabersat (15, 40, 80mg in the
International study; 25, 40, 80mg in the North American study)
or matching placebo at the onset of moderate or severe headache
symptoms. The results were analyzed for 438 patients enrolled
in the International study and 413 in the North American one.
In the International study, tonabersat was significantly more effi-
cient than placebo in relieving moderate to severe migraine pain.
Significantly more patients who received tonabersat (40mg) than
those who received placebo experienced headache relief at 2 h
(primary endpoint) or 4 h (secondary endpoint), or complete
abolition of headache at 4 h (secondary endpoint). In the North
American study, no significant benefits of tonabersat compared
to placebo were observed. In these studies, previous triptan expo-
sure appeared to affect the response to tonabersat. Moreover,
pharmacokinetic analyses indicated that tonabersat was absorbed
relatively slowly, and so required a long time to reach maxi-
mum plasma concentrations. The observed lack of efficacy may
be a function of the slow absorption of tonabersat that could
result in an insufficient therapeutic effect on acute migraine.
Delayed absorption in patients with migraine has been previously
reported during an attack and was proposed to be due to slower
gastric emptying (Aurora et al., 2006; Silberstein et al., 2009).
These pharmacokinetic characteristics indicate that tonabersat is
more suitable as a daily prophylactic drug for migraine attacks
(Silberstein, 2009).
CONCLUSIONS AND PERSPECTIVES
Gap junction channels seem to be involved at different levels in
the pathophysiology of migraine with aura. At a first level, GJIC
and Cx-made hemichannels have been proposed to be involved
in CSD propagation (Martins-Ferreira et al., 2000). The Cx36
channel blockers quinine, quinidine, and mefloquine are able to
inhibit CSD in rats in vitro, suggesting an involvement of neuronal
Cx36 channels in CSD propagation (Margineanu and Klitgaard,
2006). At a second level, the stressed neuronal Panx1 channels
have been shown to be transiently opened in response to CSD
propagation (Karatas et al., 2013). At a third level, in the TGG,
gap junctions between neuronal and satellite glial cells seem to
be involved in initiating and maintaining peripheral sensitization
(Damodaram et al., 2008). And finally, at a fourth level, in the
brainstem, it was suggested that gap junctions and/or hemichan-
nels play a role in mediating central sensitization (Chiang et al.,
2010).
Tonabersat, was selected for clinical trial on the basis of its
inhibitory activity on CSD and neurogenic inflammation in ani-
malmodels ofmigraine.Moreover, in preclinical studies, tonaber-
sat was shown to inhibit GJIC between neurons and satellite glial
cells within the TGG (Durham andGarrett, 2009). However, three
randomized, placebo-controlled, clinical trials aimed at investi-
gating the effectiveness of tonabersat as a preventive drug were
negative (Tvedskov et al., 2004; Goadsby et al., 2009b; Peroutka,
2009). Moreover, conflicting results were obtained in dose rang-
ing, placebo-controlled trials concerning its ability to relieve
attacks (Silberstein et al., 2009). In contrast, in another random-
ized, placebo-controlled, clinical trial, tonabersat showed a pre-
ventive effect on attacks of migraine with aura but had no efficacy
on non-aura attacks (Hauge et al., 2009). So, blocking CSD may
represent a target for tonabersat in preventingmigraine with aura.
Diverse anti-migraine drugs have been shown to experimentally
suppress CSD (For review, see Costa et al., 2013). Among them are
the antiepileptic drugs (gabapentin, lamotrigine, topiramate, val-
proate), the β1 blocker propranolol, the tricyclic antidepressant
amitryptiline, gepants and tonabersat. At a molecular level, these
drugs exert their inhibitory effects on CSD, based on their mech-
anisms of action. Panx1 channel activity can be modulated by
various mechanisms including activation via membrane depolar-
ization, elevated extracellular K+, ionotropic receptors (including
the NMDA glutamatergic receptor) and G protein-coupled recep-
tors (Sandilos and Bayliss, 2012). It has been proposed that the
advancing front of CSD may contribute to the trigger of the
depolarization of the surrounding neurons, leading to further
release of glutamate and K+ into the extracellular environment
(Martins-Ferreira et al., 2000). Thus, inhibition of CSD propaga-
tion and, in turn, of release of glutamate and K+, could result
in a reduced Panx1 channel activity. In the same way, inhibi-
tion of CSD, by reducing stressed neuronal Panx1 channel activity
and, in turn, iNOS induction in astrocytes forming the glia limi-
tans, could explain the potent inhibition of NO release observed
following tonabersat pre-treatment in the CSD-anaesthetized cat
model (Read et al., 2000; Karatas et al., 2013).
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The extent to which migraine with aura and migraine without
aura are different disorders has been the subject of much debate.
Tonabersat, having a preventive effect in migraine with aura but
no efficacy on non-aura attacks, suggests that an asymptomatic
CSD is not involved in attacks of migraine without aura.
Preclinical studies and clinical trials also showed that tonaber-
sat was well tolerated, with no effects on arterial blood pressure
and heart rate. Moreover, the pharmacokinetic characteristics
of tonabersat indicate that it is more suitable as a prophylac-
tic therapy for migraine attacks. Comparing with the potential
targets of currently utilized preventive drugs, tonabersat has a
unique mechanism of action without vasoconstrictive adverse
effect and might represent an interesting future possibility for the
prophylaxis of this disease. It is estimated that about a third of
migraineurs experiences aura. So, even if tonabersat benefits only
to patients suffering migraine with aura, a substantial number of
them could benefit from this drug. Moreover, the risk of ischemic
stroke is doubled in migraine with aura, particularly in young
women. The risk is greater for those with a higher frequency of
migraine attacks (Kurth et al., 2012). Furthermore, MRI studies
have shown an association between migraine with aura and a sig-
nificantly increased risk of brain lesions (Kruit et al., 2010). The
availability of a new therapeutic agent that could not only pre-
vent the immediate discomfort associated with migraine but also
potential long-term risks of repeated attacks, would be an impor-
tant step forward. Migraine-preventive agents are still under-used
while they could lower healthcare costs. The development of a
preventive medication could reduce use of drugs for acute attacks
and decreases visits tomedical office and emergency departments.
Epilepsy and migraine are chronic neurological disorders with
episodic manifestations that frequently occur together. Neuronal
hyperexcitability is an underlyingmechanistic similarity common
to both disorders. Some antiepileptic drugs have a preventive
effect in migraine without aura and possibly in migraine with
aura (Haut et al., 2006). Across a number of preclinical studies,
tonabersat also demonstrated an anti-seizure profile and is cur-
rently being evaluated in phase I studies as an investigational drug
for treating epilepsy (Bialer et al., 2013).
The pathophysiology of migraine with aura involves GJIC
between neurons and glial cells in the neocortex and TGG.
Tonabersat treatment reduced Cx26 staining and number of junc-
tional plaques in TGG cells. However, given the large number
of Cxs expressed in nervous system, it is probable that other Cx
proteins may also be regulated by tonabersat. Moreover, Panx1
channel activity at the plasma membrane being modulated by
trafficking dynamics, a potential modulation of Panx1 trafficking
by tonabersat requires experimental testing (Sandilos and Bayliss,
2012). Characterization of Cxs involved in the pathophysiology of
migraine with aura and the development of models allowing their
study are avenues to be explored in the future. This would allow
the development of new therapeutic tools to treat efficiently and
safely migraine with aura by suppressing or reducing specifically
GJIC in cell subpopulations of the nervous system.
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